Taysha Gene Therapies, Inc. (TSHA:NASDAQ) closed at $3.62 on October 16, 2026, down 2.95% on the day. The stock trades 50.4% below its 52-week high of $7.30 and 4.8% above its 52-week low of $3.46. Over the past year, it lost 23.3%. Taysha Gene Therapies, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -12.56% | -29.85% | -35.13% | -43.96% | -23.31% |
In 252 trading sessions since October 16, 2025, TSHA closed higher on 117 days (46%). Its best day was April 15, 2026 (+27.39%) and its worst was July 13, 2026 (-15.14%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 1 time.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Find more stocks like TSHA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.